URMC Related Haplo-identical Donor BMT

Inclusion Criteria

• •Patient Age:
• •Pediatric (ages 6 months to 18 years)
• •Adult (ages 18-75 years)
• •Disease:
• •Congenital and Other Non-malignant Disorders
• •Immunodeficiency disorders (e.g. Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome)
• •Congenital hematopoietic stem cell defects (e.g. Chediak-Higashi Syndrome, Congenital Osteopetrosis, Osteogenesis Imperfecta)
• •Metabolic disorders (e.g. Hurler's Syndrome)
• •Hemoglobinopathies (e.g. Sickle Cell Disease, Thalassemia)
• •Severe aplastic anemia
• •High-Risk Leukemias
• •Acute Myelogenous Leukemia
• •Refractory to standard induction therapy (more than 1 cycle required to achieve remission)
• •Recurrent (in CR≥2)
• •Treatment-related AML or MDS
• •Evolved from myelodysplastic syndrome
• •Presence of Flt3 abnormalities
• •FAB M6 or M7
• •Adverse cytogenetics
• •Myelodysplastic Syndrome
• •Acute Lymphoblastic Leukemia including T lymphoblastic leukemia
• •Refractory to standard induction therapy (time to CR \>4 weeks)
• •Recurrent (in CR ≥2)
• •WBC count \>30,000/mcL at diagnosis
• •Age \>30 at diagnosis
• •Adverse cytogenetics, such as (t(9:22), t(1:19), t(4:11), other MLL rearrangements.
• •Chronic Myelogenous Leukemia in accelerated phase or blast crisis
• •Biphenotypic or undifferentiated leukemia
• •Burkitt's leukemia or lymphoma
• •Lymphoma:
• •Large cell, Mantle cell, Hodgkin lymphoma refractory or recurrent, chemosensitive, and ineligible for an autologous stem cell transplant or previously treated with autologous SCT
• •Marginal zone or follicular lymphoma that is progressive after at least two prior therapies
• •Multiple Myeloma, recurrent following high-dose therapy and autologous SCT or ineligible for an autologous HSCT
• •Solid tumors, with efficacy of allogeneic HSCT demonstrated for the specific disease and disease status
• •Graft failure following prior related donor, unrelated donor or UCB transplant
• •Myelofibrosis